Current Clinical Trials Testing the Combination of Immunotherapy with Radiotherapy

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2016 Sep 24

PMID 27660705

Citations 197

Authors

Josephine Kang

Sandra Demaria

Silvia Formenti

Affiliations

Soon will be listed here.

Abstract

Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion in the number of clinical trials harnessing radiation to enhance antitumor immunity. If positive, results of these trials will lead to a paradigm shift in the use of radiotherapy. In this review, we discuss the rationale for trials combining radiation with various immunotherapies, provide an update of recent clinical trial results and highlight trials currently in progress. We also address issues pertaining to the optimal incorporation of immunotherapy with radiation, including sequencing of treatment, radiation dosing and evaluation of clinical trial endpoints.

Citing Articles

Radiation-Enhanced AF1q Moves Center Stage as a Key Driver to Favorable Tumor Stage in Rectal Cancer Patients.

Gruber E, Oberhuber G, Gurnhofer E, Eferl R, Timelthaler G, Teleky B Cancer Med. 2025; 14(5):e70658.

PMID: 40062505 PMC: 11891775. DOI: 10.1002/cam4.70658.

Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma.

Harada H, Hachisuga T, Harada Y, Shibahara M, Murakami M, Nuratdinova F Diagnostics (Basel). 2025; 15(4).

PMID: 40002574 PMC: 11854212. DOI: 10.3390/diagnostics15040422.

Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation.

Lee S, Pagacz J, Averbek S, Scholten D, Liu Y, Kron S Cancers (Basel). 2025; 17(3).

PMID: 39941761 PMC: 11815760. DOI: 10.3390/cancers17030391.

Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis.

Zhang H, Huang J, Xu H, Yin N, Zhou L, Xue J Front Immunol. 2025; 16:1523455.

PMID: 39931055 PMC: 11808008. DOI: 10.3389/fimmu.2025.1523455.

Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases.

Beninato T, Amin S, Baine M, Lin C Hepat Oncol. 2025; 11(1):2403323.

PMID: 39881556 PMC: 11444651. DOI: 10.1080/20450923.2024.2403323.

References

Grilli G, NOTHDURFT W, FLIEDNER T . Radiation sensitivity of human erythropoietic and granulopoietic progenitor cells in the blood and in the bone marrow. Int J Radiat Biol Relat Stud Phys Chem Med. 1982; 41(6):685-7. DOI: 10.1080/09553008214550781. View

Mason K, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg A . Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005; 11(1):361-9. View

Yovino S, Kleinberg L, Grossman S, Narayanan M, Ford E . The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013; 31(2):140-4. PMC: 3991115. DOI: 10.3109/07357907.2012.762780. View

Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D . Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271(12):907-13. View

Rekers N, Zegers C, Yaromina A, Lieuwes N, Biemans R, Senden-Gijsbers B . Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiother Oncol. 2015; 116(3):438-42. DOI: 10.1016/j.radonc.2015.06.019. View

Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I . Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut. 1998; 43(4):575-7. PMC: 1727260. DOI: 10.1136/gut.43.4.575. View

Rosenberg S, Yang J, White D, Steinberg S . Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998; 228(3):307-19. PMC: 1191483. DOI: 10.1097/00000658-199809000-00004. View

Vanpouille-Box C, Pilones K, Wennerberg E, Formenti S, Demaria S . In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. 2015; 33(51):7415-7422. PMC: 4684480. DOI: 10.1016/j.vaccine.2015.05.105. View

Slovin S, Higano C, Hamid O, Tejwani S, Harzstark A, Alumkal J . Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013; 24(7):1813-1821. PMC: 3707423. DOI: 10.1093/annonc/mdt107. View

10.

Gallucci S, Lolkema M, Matzinger P . Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999; 5(11):1249-55. DOI: 10.1038/15200. View

11.

Aguilar L, Shirley L, Chung V, Marsh C, Walker J, Coyle W . Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother. 2015; 64(6):727-36. PMC: 11029723. DOI: 10.1007/s00262-015-1679-3. View

12.

Chi K, Liu S, Li C, Kuo H, Wang Y, Chao Y . Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005; 28(2):129-35. DOI: 10.1097/01.cji.0000154248.74383.5e. View

13.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A . Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13(9):1050-9. DOI: 10.1038/nm1622. View

14.

Demaria S, Kawashima N, Yang A, Devitt M, Babb J, Allison J . Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005; 11(2 Pt 1):728-34. View

15.

Finkelstein S, Rodriguez F, Dunn M, Farmello M, Smilee R, Janssen W . Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012; 4(4):373-82. PMC: 4241355. DOI: 10.2217/imt.12.24. View

16.

Gough M, Crittenden M, Sarff M, Pang P, Seung S, Vetto J . Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010; 33(8):798-809. PMC: 3563298. DOI: 10.1097/CJI.0b013e3181ee7095. View

17.

Reits E, Hodge J, Herberts C, Groothuis T, Chakraborty M, Wansley E . Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006; 203(5):1259-71. PMC: 3212727. DOI: 10.1084/jem.20052494. View

18.

Dovedi S, Melis M, Wilkinson R, Adlard A, Stratford I, Honeychurch J . Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2012; 121(2):251-9. DOI: 10.1182/blood-2012-05-432393. View

19.

Gulley J, Arlen P, Bastian A, Morin S, Marte J, Beetham P . Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005; 11(9):3353-62. DOI: 10.1158/1078-0432.CCR-04-2062. View

20.

Seiwert T, Darga T, Haraf D, Blair E, Stenson K, Cohen E . A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2012; 24(3):769-76. PMC: 3662388. DOI: 10.1093/annonc/mds523. View